News | May 11, 2022
Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
It is India’s first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD)
Cipla has reported consolidated financial results for the period ended September 30, 2021
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
India business contributes to a stellar performance
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
Subscribe To Our Newsletter & Stay Updated
